- Home
- LNKB vs INBX Comparison
LNKB vs INBX Comparison
Compare LNKB & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- INBX
- Stock Information
- Founded
- LNKB 2018
- INBX 2010
- Country
- LNKB United States
- INBX United States
- Employees
- LNKB N/A
- INBX N/A
- Industry
- LNKB
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- INBX Health Care
- Exchange
- LNKB Nasdaq
- INBX Nasdaq
- Market Cap
- LNKB 236.7M
- INBX 237.5M
- IPO Year
- LNKB N/A
- INBX 2020
- Fundamental
- Price
- LNKB $6.46
- INBX $15.64
- Analyst Decision
- LNKB Hold
- INBX Hold
- Analyst Count
- LNKB 1
- INBX 1
- Target Price
- LNKB $7.50
- INBX N/A
- AVG Volume (30 Days)
- LNKB 44.2K
- INBX 115.8K
- Earning Date
- LNKB 10-25-2024
- INBX 08-13-2024
- Dividend Yield
- LNKB 4.82%
- INBX N/A
- EPS Growth
- LNKB N/A
- INBX N/A
- EPS
- LNKB N/A
- INBX 118.83
- Revenue
- LNKB $68,142,000.00
- INBX $1,687,000.00
- Revenue This Year
- LNKB N/A
- INBX N/A
- Revenue Next Year
- LNKB $4.03
- INBX N/A
- P/E Ratio
- LNKB N/A
- INBX $0.13
- Revenue Growth
- LNKB 101.22
- INBX 24.26
- 52 Week Low
- LNKB $5.86
- INBX $10.80
- 52 Week High
- LNKB $8.29
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- LNKB 54.07
- INBX 52.98
- Support Level
- LNKB $6.16
- INBX $14.67
- Resistance Level
- LNKB $6.39
- INBX $16.35
- Average True Range (ATR)
- LNKB 0.13
- INBX 0.58
- MACD
- LNKB 0.00
- INBX -0.08
- Stochastic Oscillator
- LNKB 76.92
- INBX 57.74
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.